Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production

 
• By Joseph Haas

Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.

Fourth quarter
Lilly intends to increase production capacity for Mounjaro ahead of obesity approval • Source: Shutterstock

More from Earnings

More from Business